Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients
Tóm tắt
A randomized trial was conducted to compare the efficacy and safety of fluconazole versus that of amphotericin B in the treatment of candidemia in non-neutropenic adults. Enrollment was stratified by disease severity (APACHE II score). Patients were randomized (1∶:1) to receive amphotericin B 0.6 mg/kg/day (cumulative dose 8 mg/kg) or fluconazole 800 mg intravenous loading dose, then 400 mg daily for four weeks (intravenous for at least 10 days). Patients were monitored for six months. A total of 106 patients were enrolled. A protocol amendment implemented midway through the trial required patients to be removed from the study and treated with amphotericin B if species identification indicated candidemia due toCandida glabrata orCandida krusei. Baseline characteristics were similar for the two groups; 103 patients (fluconazole, 50; amphotericin B, 53) met the major enrollment criteria. The intention-to-treat analysis indicated successful therapy in 50% of fluconazole recipients compared to 58% of the amphotericin B group (p=0.39; one-sided 95% Cl, −8 to 24%). The efficacy analysis included 84 patients (fluconazole, 42; amphotericin B, 42); successful outcomes were observed in 57% and 62% of cases in the fluconazole and amphotericin B groups, respectively (p=0.66: one-sided 95% Cl, −12 to 22%). The mortality at day 14 for the fluconazole group was 26% and for the amphotericin B group 21% (p=0.52; chi-square test) and remained similar throughout the course of follow-up. Drug-related adverse events were more frequent with amphotericin B than with fluconazole and prompted switching of therapy for two (4%) and zero cases, respectively. Fluconazole and amphotericin B were associated with similar clinical response rates and survival in the treatment of candidemia among non-neutropenic patients; however, drug-related adverse events were more frequent with amphotericin B.
Tài liệu tham khảo
Banerjee SN, Emori TG, Culver DH, Gaynes RP, Jarvis WR, Horan T, Edwards JR, Tolson J, Henderson T, Martone WJ, and the National Nosocomial Infections Surveillance System: Secular trends in nosocomial primary bloodstream infections in the United States, 1980–1989. American Journal of Medicine 1991, 91, Supplement 3B: 86–89.
Fraser VJ, Jones M, Dunkel J, Storfer S, Medoff G, Dunagan WC: Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clinical Infectious Diseases 1992, 15: 414–421.
Komshian SV, Uwaydah AK, Sobel JD, Crane LR: Fungemia caused byCandida species andTorulopsis glabrata in the hospitalized patient: frequency, characteristics, and evaluation of factors influencing outcome. Reviews of Infectious Diseases 1989, 11: 379–390.
Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP: Hospital-acquired candidemia. The attributable mortality and excess length of stay. Archives of Internal Medicine 1988, 148: 2642–2645.
Lecciones JA, Lee JW, Navarro EE, Witebsky EG, Marshall D, Steinberg SM, Pizzo PA, Walsh TJ: Vascular catheter-associated fungemia in patients with cancer: analysis of 155 episodes. Clinical Infectious Diseases 1992, 14: 875–883.
Horn R, Wong B, Kiehn TE, Armstrong D: Fungemia in a cancer hospital: changing frequency, earlier onset, and results of therapy. Reviews of Infectious Diseases 1985, 7: 646–655.
Rose HD: Venous catheter-associated candidemia. American Journal of the Medical Sciences 1978, 275: 265–269.
Edwards JE Jr, Filler SG: Current strategies for treating invasive candidiasis: emphasis on infections in non-neutropenic patients. Clinical Infectious Diseases 1992, 14, Supplement 1: 106–113.
Edwards JE Jr: Should all patients with candidemia be treated with antifungal agents? Clinical Infectious Diseases 1992, 15: 422–423.
Goa KL, Barradell LB: Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients. Drugs 1995, 50: 658–690.
Anaissie E, Bodey GP, Kantarjian H, David C, Barnett K, Bow E, Defelice R, Downs N, File T, Karam G, Potts D, Shelton M, Sugar A: Fluconazole therapy for chronic disseminated candidiasis in patients with leukemia and prior amphotericin B therapy. American Journal of Medicine 1991, 91: 142–150.
Rex JH, Bennett JE, Sugar AM, Pappas PG, van der Horst CM, Edwards JE, Washburn RG, Scheld WM, Karchmer AW, Dine AP, Levenstein MJ, Webb CD, for the Candidemia Study Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group: A randomized trial comparing fluconazole with amphotericin B for the treatment of candidema in patients without neutropenia. New England Journal of Medicine 1994,331: 1325–1330.
Wingard JR, Merz WG, Rinaldi MG, Johnson TR, Karp JE, Saral R: Increase inCandida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. New England Journal of Medicine 1991, 325: 1274–1277.
Evans TG, Mayer J, Cohen S, Classen D, Carroll K: Fluconazole failure in the treatment of invasive mycoses. Journal of Infectious Diseases 1991, 164: 1232–1235.
Wingard JR, Merz WG, Rinaldi MG, Miller CB, Karp JE, Saral R: Association ofTorulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrobial Agents and Chemotherapy 1993, 37: 1847–1849.
Warnock DW, Burke J, Cope NJ, Johnson EM, von Fraunhofer NA, Williams EW: Fluconazole resistance inCandida glabrata. Lancet 1988, ii: 1310.
Edwards JE Jr, Foos RY, Montgomerie JZ, Guze LB: Ocular manifestations ofCandida septicemia: review of seventy-six cases of hematogenousCandida endophthalmitis. Medicine 1974, 53: 47–75.
Anaissie EJ, Vartivarian SE, Abi-Said D, Uzun O, Pinczowski H, Kontoyiannis DP, Khoury P, Papadakis K, Gardner A, Raad II, Gilbreath J, Bodey GP: Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: a matched cohort study. American Journal of Medicine 1996, 101: 170–176.
Galgiani JN: Susceptibility ofCandida albicans and other yeasts to fluconazole: relation between in vitro and in vivo studies. Reviews of Infectious Diseases 1990, 12, Supplement 3: 272–275.
Rex JH, Pfaller MA, Barry AL, Nelson PW, Webb CD, for the NIAID Mycoses Study Group and the Candidemia Study Group: Antifungal susceptibility testing of isolates from a randomized multicenter trial of fluconazole versus amphotericin B as treatment of non-neutropenic patients with candidemia. Antimicrobial Agents and Chemotherapy 1995, 39: 40–44.
Rex JH, Rinaldi MG, Pfaller MA: Resistance ofCandida species to fluconazole. Antimicrobial Agents and Chemotherapy 1995, 39: 1–8.
Parkinson T, Falconer DJ, Hitchcock CA: Fluconazole resistance due to energy-dependent drug efflux inCandida glabrata. Antimicrobial Agents and Chemotherapy 1995, 39: 1696–1699.
Sanglard D, Kuchler K, Ischer F, Pagani J-L, Monod M, Bille J: Mechanisms of resistance to azole antifungal agents inCandida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrobial Agents and Chemotherapy 1995, 39: 2378–2386.
Rex JH, Pfaller MA, Rinaldi MG, Polak A, Galgiani JN: Antifungal susceptibility testing. Clinical Microbiology Reviews 1993, 6: 367–381.
Graybill JR, Najvar LK, Holmberg JD, Correa A, Luther MF: Fluconazole treatment ofCandida albicans infection in mice: Does in vitro susceptibility predict in vivo response? Antimicrobial Agents and Chemotherapy 1995, 39: 2197–2200.
Atkinson BA, Bouthet G, Bocanegra R, Correa A, Luther MF, Graybill JR: Comparison of fluconazole, amphotericin B and flucytosine in treatment of a murine model of disseminated infection withCandida glabrata in immunocompromised mice. Journal of Antimicrobial Chemotherapy 1995, 35: 631–640.
Price MF, LaRocco MT, Gentry LO: Fluconazole susceptibilities ofCandida species and distribution of species recovered from blood cultures over a 5-year period. Antimicrobial Agents and Chemotherapy 1994, 38: 1422–1424.
Tiballi RN, Zarins LT, He X, Kauffman CA:Torulopsis glabrata: azole susceptibilities by microdilution colorimetric and macrodilution broth assays. Journal of Clinical Microbiology 1995, 33: 2612–2615.
Nguyen MH, Peacock JE Jr, Tanner DC, Morris AJ, Nguyen ML, Snydman DR, Wagener MM, Yu VL: Therapeutic approaches in patients with candidemia. Archives of Internal Medicine 1995, 155: 2429–2435.
Moyer DV, Edwards JE Jr: Candida endophthalmitis and central nervous system infection. In: Bodey GP (ed): Candidiasis: pathogenesis, diagnosis and treatment. Raven Press, New York, 1993, p. 331–355.
Filler SG, Crislip MA, Mayer CL, Edwards JE Jr: Comparison of fluconazole and amphotericin B for treatment of disseminated candidiasis and endophthalmitis in rabbits. Antimicrobial Agents and Chemotherapy 1991, 35: 288–292.
Park SS, D'Amico DJ, Paton B, Sullivan Baker A: Treatment of exogenousCandida endophthalmitis in rabbits with oral fluconazole. Antimicrobial Agents and Chemotherapy 1995, 39: 958–963.